Increased expression of the 88-kDa glycoprotein (GP88/PGRN) has been reported, e.g., in breast cancer, brain tumors, ovarian cancer, renal carcinoma, bladder cancer, non-small cell lung cancer, and hematological cancers [12,13,14,15,16]. This evidence concerns the gene GRN and brain neoplasm.